The Hindu·3 min read·medium
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe
✦AI Summary
Shilpa Medicare has partnered with Orion Corporation to develop and supply a nivolumab biosimilar for the European market. This agreement aims to increase patient access to cancer immunotherapy by providing a more affordable alternative to the original drug.
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe.
healthbusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in